We are live on ! Find out more
KITE

Kite Pharma, Inc.
KITE

Delisted

KITE was delisted on the 2nd of October, 2017.

187 hedge funds and large institutions have $2.26B invested in Kite Pharma, Inc. in 2015 Q4 according to their latest regulatory filings, with 50 funds opening new positions, 64 increasing their positions, 48 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

194% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 17

33% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 48

22% more capital invested

Capital invested by funds: $1.86B → $2.26B (+$399M)

21% more funds holding

Funds holding: 155187 (+32)

5% more call options, than puts

Call options by funds: $29.7M | Put options by funds: $28.2M

17% less funds holding in top 10

Funds holding in top 10: 65 (-1)

Holders
187
Holders Change
+32
Holders Change %
+20.65%
% of All Funds
4.91%
Holding in Top 10
5
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-16.67%
% of All Funds
0.13%
New
50
Increased
64
Reduced
48
Closed
17
Calls
$29.7M
Puts
$28.2M
Net Calls
+$1.51M
Net Calls Change
-$5.51M
Name Holding Trade Value Shares
Change
Change in
Stake
RHJA
76
Rice Hall James & Associates
California
$2.44M +$1.18M +16,820 +74%
Dimensional Fund Advisors
77
Dimensional Fund Advisors
Texas
$2.09M +$2.39M +33,891 New
Bank of America
78
Bank of America
North Carolina
$2.09M +$235K +3,333 +11%
SAM
79
Shikiar Asset Management
New York
$1.97M
AQR Capital Management
80
AQR Capital Management
Connecticut
$1.95M -$854K -12,139 -28%
New York State Common Retirement Fund
81
New York State Common Retirement Fund
New York
$1.93M -$1.29M -18,359 -37%
PA
82
Profund Advisors
Maryland
$1.88M +$194K +2,760 +10%
GH
83
GAM Holding
Switzerland
$1.87M +$1.57M +22,300 +275%
CC
84
Casdin Capital
New York
$1.85M +$2.11M +30,000 New
CS
85
Credit Suisse
Switzerland
$1.82M +$840K +11,927 +68%
RhumbLine Advisers
86
RhumbLine Advisers
Massachusetts
$1.77M +$187K +2,660 +10%
FAM
87
Fred Alger Management
New York
$1.66M +$1.89M +26,853 New
CAM
88
CG Asset Management
New York
$1.62M +$1.11M +15,760 +149%
JG
89
Jefferies Group
New York
$1.58M -$2.82M -40,100 -61%
Baird Financial Group
90
Baird Financial Group
Wisconsin
$1.53M +$121K +1,721 +7%
Wells Fargo
91
Wells Fargo
California
$1.52M -$293K -4,168 -14%
TAM
92
Tocqueville Asset Management
New York
$1.45M -$38.7K -550 -2%
NFA
93
Nationwide Fund Advisors
Ohio
$1.45M -$142K -2,014 -8%
LPL Financial
94
LPL Financial
California
$1.43M +$719K +10,220 +81%
DekaBank Deutsche Girozentrale
95
DekaBank Deutsche Girozentrale
Germany
$1.39M +$42.2K +600 +3%
Morgan Stanley
96
Morgan Stanley
New York
$1.33M +$52K +739 +4%
Jane Street
97
Jane Street
New York
$1.32M +$834K +11,843 +125%
MIG
98
Mariner Investment Group
New York
$1.29M -$352K -5,000 -19%
MLICM
99
Metropolitan Life Insurance Company (MetLife)
New York
$1.24M
BG
100
BlackRock Group
United Kingdom
$1.2M +$418K +5,943 +44%

KITE Hedge Fund Activity: Q4 2015 in Review

187 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Kite Pharma, Inc. (KITE) for Q4 2015, worth a combined $2.26B — up 22% from $1.86B a quarter earlier.

Buyers outnumbered sellers: 50 funds opened new KITE positions and 17 closed out — a net gain of 33 holders — while 64 added to existing stakes and 48 trimmed.

The largest buyer was JP Morgan Chase, adding an estimated $51.4M. The largest seller was Frontier Capital Management, cutting an estimated $33.9M.

  • 187 institutional investors held Kite Pharma, Inc. (KITE) as of Q4 2015, up from 155 in Q3 2015.
  • Funds reported $2.26B of Kite Pharma, Inc. stock for Q4 2015, up 22% quarter-over-quarter.
  • 50 funds opened new Kite Pharma, Inc. positions in Q4 2015 and 17 closed out, a net change of +33 holders.
  • The largest Kite Pharma, Inc. buyer in Q4 2015 was JP Morgan Chase, an estimated $51.4M added.
  • The largest Kite Pharma, Inc. seller in Q4 2015 was Frontier Capital Management, an estimated $33.9M sold.

Based on aggregated 13F filings for Q4 2015.